Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul;168(1):23-9.e2.
doi: 10.1016/j.ahj.2014.03.021. Epub 2014 Apr 5.

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

Rury R Holman  1 , Mary A Bethel  2 , Juliana C N Chan  3 , Jean-Louis Chiasson  4 , Zoë Doran  2 , Junbo Ge  5 , Hertzel Gerstein  6 , Yong Huo  7 , John J McMurray  8 , Lars Ryden  9 , Winitha Liyanage  2 , Stefan Schröder  10 , Michal Tendera  11 , Michael J Theodorakis  2 , Jaakko Tuomilehto  12 , Wenying Yang  13 , Dayi Hu  14 , Changyu Pan  15 ; ACE Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

Rury R Holman et al. Am Heart J. 2014 Jul.

Abstract

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.

PubMed Disclaimer

Publication types

MeSH terms